Cardiovascular Therapeutics
Overview
Cardiovascular Therapeutics is a peer-reviewed journal dedicated to advancing the understanding and treatment of cardiovascular diseases. It publishes cutting-edge research on novel therapeutic approaches, clinical trials, and innovative interventions aimed at improving patient outcomes in the field of cardiology. With a focus on evidence-based medicine, this journal serves as a valuable resource for healthcare professionals, researchers, and policymakers involved in cardiovascular care.
Details
Details
Abbr.
Cardiovasc Ther
Publisher
Hindawi
Start
2008
End
Continuing
Frequency
Four no. a year
p-ISSN
1755-5914
e-ISSN
1755-5922
Country
United Kingdom
Language
English
Metrics
Metrics
h-index / Ranks: 6817
54
SJR / Ranks: 5583
769
CiteScore / Ranks: 5824
4.50
JIF / Ranks: 3327
3.1
Recent Articles
1.
Ai W, Li F, Yang Q, Qiu J, Zhou A, Huang Y, et al.
Cardiovasc Ther
. 2025 Mar;
2025:7907049.
PMID: 40046137
Identifying high-risk patients with acute pulmonary embolism is vital for improving disease prognosis. However, current guidelines and research on risk factors are insufficient to meet clinical needs. This study was...
2.
Luo Z, Lv L
Cardiovasc Ther
. 2025 Mar;
2025:8098173.
PMID: 40040886
Recent studies have indicated that cluster of differentiation 36 (CD36) is closely linked to dyslipidemia and early-onset coronary artery disease (EOCAD). This study is aimed at investigating the impacts of...
3.
Fan M, Li N, Huang L, Chen C, Dong X, Gao W
Cardiovasc Ther
. 2025 Mar;
2025:5711316.
PMID: 40026415
Cardiovascular diseases (CVDs) encompass a group of diseases that affect the heart and/or blood vessels, making them the leading cause of global mortality. In our study, we performed proteome-wide Mendelian...
4.
Atak E, Atac A
Cardiovasc Ther
. 2025 Mar;
2025:6460951.
PMID: 40026414
Breath and brain activity have been integral to daily life since time immemorial. Cognition and cardiorespiratory responses are closely interlinked, necessitating further investigation into their dynamics. The potential benefits of...
5.
Wu J, Lan Q, Zhang D, Jian Y, Yu L, Hao R, et al.
Cardiovasc Ther
. 2025 Feb;
2025:5178894.
PMID: 40018377
The NACHT, leucine-rich repeat, and pyrin domain-containing protein 3 (NLRP3) inflammasome plays an essential role in myocardial infarction (MI) development. Up to now, no bibliometric analyses of NLRP3 in MI...
6.
Lin Z, Xu Z, Chen L, Dai X
Cardiovasc Ther
. 2025 Feb;
2025:8872143.
PMID: 39996096
Atrial fibrillation (AF) complicates cardiac surgery, including valve replacements, increasing perioperative risk and impacting long-term outcomes. Concomitant radiofrequency ablation (RFA) during cardiac surgeries shows promise for managing AF. This study...
7.
Wei Y, Xiong J, Li X, Ling F, Zhao Y, Sun Y, et al.
Cardiovasc Ther
. 2025 Feb;
2025:7134878.
PMID: 39980940
This systematic review and meta-analysis of randomized controlled trials (RCTs) is aimed at assessing the clinical efficacy and safety of stellate ganglion block (SGB) for angina pectoris (AP). PubMed, Embase,...
8.
Zhang R, Wang P, Jin Y, Xie Q, Xiao P
Cardiovasc Ther
. 2025 Jan;
2025():7551459.
PMID: 39834616
Myocardial infarction (MI), a severe cardiovascular disease, is the result of insufficient blood supply to the myocardium. Despite the improvements of conventional therapies, new approaches are needed to improve the...
9.
Bheleel O, Abdulhamid A, Elmuaget H, Grash H, Abdelhamid M, Alhadi I
Cardiovasc Ther
. 2025 Jan;
2025:1396974.
PMID: 39830781
Coronary artery disease (CAD) is the leading cause of death worldwide in both men and women. Accordingly, we retrospectively reviewed the effects of various risk factors on coronary angiographic outcomes....
10.
Oh S, Cheon S, Choi S, Kim Y, Choi H, Chung J
Cardiovasc Ther
. 2025 Jan;
2025:9923772.
PMID: 39817158
Dose adjustments of direct-acting oral anticoagulants (DOACs) for atrial fibrillation are based on pivotal clinical trials assessing their effectiveness and safety in controlled settings. However, the appropriateness of these dosing...